Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral ustekinumab biosimilar - Rani Therapeutics

Next Previous
X
Search
Drug Profile

Oral ustekinumab biosimilar - Rani Therapeutics

Alternative Names: RT-111

Latest Information Update: 08 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rani Therapeutics
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Crohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis

Most Recent Events

  • 06 Aug 2024 Pharmacokinetics data from preclinical study in Obesity release by Rani Therapeutics
  • 05 Feb 2024 Adverse events and pharmacokinetics data from a phase I trial in Psoriasis, Psoriatic arthritis, Ulcerative colitis and Crohn's disease (In volunteers) released by Rani Therapeutics
  • 28 Nov 2023 RANI Therapeutics completed phase I trial in Crohn's disease (In volunteers) in Australia (PO) (NCT05890118)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top